{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:12:50Z","timestamp":1792793570635,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.iotech.2024.100704","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T14:30:56Z","timestamp":1704465056000},"page":"100704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities"],"prefix":"10.1016","volume":"21","author":[{"given":"J.","family":"McKenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sneath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2024.100704_bib1","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.iotech.2024.100704_bib2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iotech.2024.100704_bib7","article-title":"Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100787","article-title":"Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies","volume":"8","author":"Amoroso","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.iotech.2024.100704_bib9","doi-asserted-by":"crossref","first-page":"S936","DOI":"10.1016\/j.annonc.2022.07.972","article-title":"846P Triple combination of ipilimumab\u00a0+ nivolumab\u00a0+ anti-TNF in treatment naive melanoma patients: final analysis of TICIMEL, a phase Ib prospective clinical trial","volume":"33","author":"Meyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.iotech.2024.100704_bib10","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"issue":"7756","key":"10.1016\/j.iotech.2024.100704_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-019-1162-y","article-title":"Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"569","author":"Perez-Ruiz","year":"2019","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.iotech.2024.100704_bib12","doi-asserted-by":"crossref","first-page":"5993","DOI":"10.1158\/1078-0432.CCR-21-1283","article-title":"Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy","volume":"27","author":"Bai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.iotech.2024.100704_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.iotech.2024.100704_bib14","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib15","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"11","key":"10.1016\/j.iotech.2024.100704_bib16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor\u2013associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.iotech.2024.100704_bib17","article-title":"Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.iotech.2024.100704_bib18","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41591-022-01965-2","article-title":"Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome","volume":"28","author":"Simpson","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.iotech.2024.100704_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/hep.32215","article-title":"Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.iotech.2024.100704_bib24","first-page":"5490","article-title":"Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis","volume":"10","author":"Alexander","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"4","key":"10.1016\/j.iotech.2024.100704_bib25","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1093\/oncolo\/oyac019","article-title":"Efficacy of infliximab dose escalation in patients with refractory immunotherapy-related colitis: a case series","volume":"27","author":"Harris","year":"2022","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.iotech.2024.100704_bib26","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1148\/radiol.2021210814","article-title":"Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study","volume":"301","author":"Faron","year":"2021","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib28","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.cell.2019.08.008","article-title":"Single-cell analysis of Crohn\u2019s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy","volume":"178","author":"Martin","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib29","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.acvd.2021.12.001","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis","volume":"115","author":"Ederhy","year":"2022","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib32","first-page":"356","article-title":"Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury","volume":"114","author":"Fern\u00e1ndez-Gord\u00f3n S\u00e1nchez","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc2031717","article-title":"Ustekinumab for refractory colitis associated with immune checkpoint inhibitors","volume":"384","author":"Thomas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iotech.2024.100704_bib34","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.14309\/ajg.0000000000002332","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Thomas","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.iotech.2024.100704_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.iotech.2024.100704_bib36","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.iotech.2024.100704_bib37","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1200\/JOP.18.00703","article-title":"Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes","volume":"15","author":"Balaji","year":"2019","journal-title":"J\u00a0Oncol Pract"},{"issue":"suppl 1","key":"10.1016\/j.iotech.2024.100704_bib38","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.iotech.2024.100704_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.iotech.2024.100704_bib40","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2022.2081","article-title":"Association between toxic effects and survival in patients with cancer and autoimmune disease treated with checkpoint inhibitor immunotherapy","volume":"8","author":"Han","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.iotech.2024.100704_bib41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.iotech.2024.100704_bib42","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/cei.13502","article-title":"Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis","volume":"202","author":"Sasson","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib44","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","article-title":"Molecular pathways of colon inflammation induced by cancer immunotherapy","volume":"182","author":"Luoma","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2019.06.029","article-title":"Intra- and inter-cellular rewiring of the human colon during ulcerative colitis","volume":"178","author":"Smillie","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.iotech.2024.100704_bib46","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1053\/j.gastro.2021.06.025","article-title":"Interferon-gamma-producing CD8+ tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis","volume":"161","author":"Sasson","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.iotech.2024.100704_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/07357907.2017.1324032","article-title":"Immunological characteristics of colitis associated with anti-CTLA-4 antibody therapy","volume":"35","author":"Bamias","year":"2017","journal-title":"Cancer Invest"},{"issue":"8","key":"10.1016\/j.iotech.2024.100704_bib48","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-021-01406-6","article-title":"Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade","volume":"27","author":"Andrews","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib50","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.iotech.2024.100704_bib51","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S2468-1253(20)30014-5","article-title":"British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.iotech.2024.100704_bib52","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib53","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/j.gastro.2020.10.029","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib54","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal photopheresis for colitis induced by checkpoint-inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"10.1016\/j.iotech.2024.100704_bib55","first-page":"3067","article-title":"Fecal microbiota transplantation (FMT) for immune checkpoint inhibitor induced\u2013colitis (IMC) refractory to immunosuppressive therapy","volume":"38","author":"Wang","year":"2020"},{"issue":"suppl 16","key":"10.1016\/j.iotech.2024.100704_bib56","article-title":"First-line treatment of fecal microbiota transplantation for immune-mediated colitis","volume":"41","author":"Wang","year":"2023"},{"key":"10.1016\/j.iotech.2024.100704_bib57","article-title":"Antitumor effects of fecal microbiota transplantation: implications for microbiome modulation in cancer treatment","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib59","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.iotech.2024.100704_bib60","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib62","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"17","key":"10.1016\/j.iotech.2024.100704_bib63","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A\u00a0randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.iotech.2024.100704_bib64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib65","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/jgh.14889","article-title":"Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor","volume":"35","author":"Sawada","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jhep.2016.11.015","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib67","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Path"},{"issue":"12","key":"10.1016\/j.iotech.2024.100704_bib68","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1016\/j.apsb.2021.10.003","article-title":"Mechanisms of immune checkpoint inhibitor-mediated liver injury","volume":"11","author":"Shojaie","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.iotech.2024.100704_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jhep.2021.02.008","article-title":"Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis","volume":"75","author":"Gudd","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"31","key":"10.1016\/j.iotech.2024.100704_bib70","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029473","article-title":"Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: a case report","volume":"101","author":"Eleftheriotis","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.iotech.2024.100704_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101619","article-title":"The current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity","volume":"28","author":"Xing","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.iotech.2024.100704_bib73","article-title":"Effectiveness of immunosuppressant use for the treatment of immune checkpoint inhibitor-induced liver injury: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jtho.2020.09.007","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor\u2013related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2024.100704_bib75","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.iotech.2024.100704_bib76","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cgh.2022.03.050","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.iotech.2024.100704_bib77","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.iotech.2024.100704_bib78","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.iotech.2024.100704_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib80","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: endomyocardial biopsy provides pathological insights to dual diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1016\/j.iotech.2024.100704_bib81","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.iotech.2024.100704_bib82","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T\u00a0cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.iotech.2024.100704_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.iotech.2024.100704_bib84","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2024.100704_bib85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.122.062551","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.iotech.2024.100704_bib86","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.iotech.2024.100704_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc Pathol"},{"issue":"5","key":"10.1016\/j.iotech.2024.100704_bib88","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","article-title":"Immune checkpoint inhibitor myocarditis treatment strategies and future directions","volume":"4","author":"Moslehi","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"41","key":"10.1016\/j.iotech.2024.100704_bib89","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.iotech.2024.100704_bib90","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.iotech.2024.100704_bib91","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: a comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.iotech.2024.100704_bib92","article-title":"Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series","volume":"11","author":"Coustal","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.iotech.2024.100704_bib93","first-page":"2627","article-title":"Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR","volume":"9","author":"Bayless","year":"2021","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018824000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018824000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:09:05Z","timestamp":1762909745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018824000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":92,"alternative-id":["S2590018824000017"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2024.100704","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2024.100704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100704"}}